Therapy for Recurrent High-Grade Epithelial Ovarian Cancer—The Current Status and Future Trends

Abstract Ovarian malignancy is the seventh most frequently diagnosed cancer among women. The common type epithelial ovarian cancer. Several subtypes with distinct biological and molecular properties exist, there inconsistency in availability of access to different modalities treatment. standard first-line management combining surgery platinum-based chemotherapy. Most them are at an advanced stage due which they have poor outcomes. existing screening tests a low predictive value. Even best available upfront treatment, high rates recurrences observed. As result, been major advances treatment development anti-angiogenic agents PARP inhibitors. It has led improvement survival quality life relapsed cancers. This review focused on recurrent cancers future directions based current evidence. application personalized structured approach will meaningfully bring changes paradigm care these groups patients.